1700023A16Rik Activators encompass a range of chemical compounds that, through various signaling pathways, specifically enhance the functional activity1700023A16Rik Activators encompass a range of chemical compounds that, through various signaling pathways, specifically enhance the functional activity of 1700023A16Rik. Forskolin, by raising intracellular cAMP levels, indirectly potentiates 1700023A16Rik's activity by activating protein kinase A, which in turn could phosphorylate proteins within pathways involving 1700023A16Rik. Similarly, Ionomycin, through its role as a calcium ionophore, may augment 1700023A16Rik by increasing calcium concentrations and activating calcium-dependent kinases that interact with processes regulated by 1700023A16Rik. PMA, a known activator of protein kinase C, could lead to phosphorylation events that propagate signaling cascades enhancing the functional role of 1700023A16Rik. Additionally, IBMX, by preventing the breakdown of cAMP, and EGCG, through its kinase inhibitory effects, could each contribute to an increased activity of 1700023A16Rik by modulating signaling networks in which this protein is a critical component.
Inhibitors of specific pathways such as LY294002, U0126, SB203580, and Staurosporine are included due to their potential to shift signaling dynamics favorably towards pathways that utilize 1700023A16Rik. LY294002, by targeting PI3K, and U0126, by inhibiting MEK, could indirectly enhance the activity of 1700023A16Rik by dampening competing signaling routes. SB203580 acts similarly by impeding p38 MAPK activity, which may unburden pathways that engage 1700023A16Rik. Staurosporine, despite its broad kinase inhibition profile, could enable the activation of 1700023A16Rik by inhibiting kinases that otherwise suppress 1700023A16Rik-related pathways. Sphingosine-1-phosphate and Thapsigargin each play distinct roles in modulating lipid and calcium signaling, respectively, which could amplify the activity of 1700023A16Rik by initiating signaling processes that intersect with 1700023A16Rik's function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, potentially enhancing 1700023A16Rik activity by activating calcium-dependent protein kinases that could phosphorylate 1700023A16Rik or associated regulatory proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could lead to the phosphorylation of proteins that interact with 1700023A16Rik, thereby enhancing its function in cellular signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels which might enhance 1700023A16Rik activity through cAMP-dependent pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that might enhance 1700023A16Rik activity by inhibiting kinases that negatively regulate pathways in which 1700023A16Rik is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could enhance 1700023A16Rik activity by reducing competitive PI3K/Akt signaling, potentially allowing pathways involving 1700023A16Rik to become more prominent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could enhance 1700023A16Rik activity by reducing p38 MAPK signaling, which may relieve negative feedback on pathways involving 1700023A16Rik. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate modulates sphingolipid signaling, which could enhance 1700023A16Rik activity by activating sphingosine kinase and subsequent signaling pathways that interact with processes involving 1700023A16Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which could enhance 1700023A16Rik activity by increasing cytosolic calcium levels and activating calcium-dependent signaling pathways that interact with 1700023A16Rik. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that might selectively enhance 1700023A16Rik activity by inhibiting kinases that negatively regulate pathways in which 1700023A16Rik is involved. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that could enhance 1700023A16Rik activity by inhibiting competitive signaling pathways, potentially allowing for the activation of pathways where 1700023A16Rik plays a role. | ||||||